Myrna Francis - Covalon Technologies Independent Director
COV Stock | CAD 3.74 0.09 2.47% |
Director
Dr. Myrna Francis is Independent Director of the Company. Dr. Francis has an extensive background in healthcare and is well known in both private and public sectors her experience spans the international marketplace Canada, the US, and Europe. She is currently the President of Mfran Healthcare Advisory Services. She is the Vice Chair of OCAD University Board of Governors and serves as a Board Director at Medavie Inc. and as a volunteer advisor for BioMedical Zone and MaRS Discovery District, Health Ventures Group. Dr. Francis has previously held positions as the CEO of Canada Health Infoway, Vice President, Global Healthcare Sector, at CGI Group Inc., Partner at CSC Healthcare Group, and numerous executive positions with the Ontario Ministry of Health. She has also served as a Board Director for a variety of companies and organizations, including RxCanada, Allstate Insurance Company of Canada, and Cedara Software Corporationration She currently provides strategic advisory services in the public sector and to multinational private sector companies regarding health information technology, business transformation, business and product growth strategies, and innovation as an independent consultant since 2019.
Tenure | 5 years |
Address | 1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7 |
Phone | 905 568 8400 |
Web | https://www.covalon.com |
Covalon Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0325) % which means that it has lost $0.0325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0385) %, meaning that it generated substantial loss on money invested by shareholders. Covalon Technologies' management efficiency ratios could be used to measure how well Covalon Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.22 in 2024. At this time, Covalon Technologies' Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to climb to about 637.1 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 115.6 K in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Craig Broderick | Bank of Montreal | 59 | |
David Denison | Royal Bank of | 66 | |
Michael Penner | Bank of Nova | 49 | |
Toos Daruvala | Royal Bank of | 63 | |
Jeffery Yabuki | Royal Bank of | 59 | |
Tiff Macklem | Bank of Nova | 57 | |
Colleen Goggins | Toronto Dominion Bank | 64 | |
Raymond Chun | Toronto Dominion Bank | N/A | |
David Harquail | Bank of Montreal | 62 | |
Alan MacGibbon | Toronto Dominion Bank | 63 | |
Michael McCain | Royal Bank of | 60 | |
Ronald Farmer | Bank of Montreal | 68 | |
Karen Maidment | Toronto Dominion Bank | 60 | |
Brian Ferguson | Toronto Dominion Bank | 62 | |
Charles Dallara | Bank of Nova | 70 | |
Heather MunroeBlum | Royal Bank of | 68 | |
Lorraine Mitchelmore | Bank of Montreal | 56 | |
Benita Warmbold | Bank of Nova | 60 | |
Nadir Mohamed | Toronto Dominion Bank | 63 | |
Indira Samarasekera | Bank of Nova | 66 | |
Nora Aufreiter | Bank of Nova | 59 |
Management Performance
Return On Equity | -0.0385 | ||||
Return On Asset | -0.0325 |
Covalon Technologies Leadership Team
Elected by the shareholders, the Covalon Technologies' board of directors comprises two types of representatives: Covalon Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Covalon. The board's role is to monitor Covalon Technologies' management team and ensure that shareholders' interests are well served. Covalon Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Covalon Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Simon Smith, Chief Ltd | ||
John Hands, Senior Director - Global Marketing | ||
Greg Leszczynski, Vice Resources | ||
Brent Ashton, CEO Director | ||
Hamed Abbasian, Vice Development | ||
Ian Brindle, Independent Director | ||
Elaine Zhang, Vice Operations | ||
Mark Doolittle, Senior Operations | ||
Joseph Cordiano, Independent Director | ||
Valerio DiTizio, Co-Founder and Chief Science Officer | ||
Ronald Smith, Director | ||
Gerry Arambula, President Ltd | ||
Emily Hill, Executive CEO | ||
Elinor Caplan, Director | ||
Murray Miller, Independent Director | ||
Kim Crooks, Vice President - Operations | ||
Ron Hebert, VP Marketing | ||
Gale Pollock, Director | ||
Amir CFA, Executive Chairman | ||
Jeffrey Mandel, Independent Director | ||
Myrna Francis, Independent Director | ||
Katie Martinovich, Interim Officer | ||
Danny Brannagan, Chief Financial Officer | ||
Brian Pedlar, President, Chief Executive Officer, Director | ||
John Suk, Director | ||
Ronald Hebert, Senior Marketing | ||
Jason Gorel, Interim Officer | ||
Abe Schwartz, Chairman of The Board, Advisor and Member of Audit Committee |
Covalon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Covalon Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0385 | ||||
Return On Asset | -0.0325 | ||||
Profit Margin | (0.03) % | ||||
Operating Margin | 0.16 % | ||||
Current Valuation | 94.14 M | ||||
Shares Outstanding | 27.4 M | ||||
Shares Owned By Insiders | 48.69 % | ||||
Number Of Shares Shorted | 1.89 K | ||||
Price To Earning | 69.86 X | ||||
Price To Book | 4.73 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Covalon Stock Analysis
When running Covalon Technologies' price analysis, check to measure Covalon Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Covalon Technologies is operating at the current time. Most of Covalon Technologies' value examination focuses on studying past and present price action to predict the probability of Covalon Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Covalon Technologies' price. Additionally, you may evaluate how the addition of Covalon Technologies to your portfolios can decrease your overall portfolio volatility.